Author Archives: admin


Stem Cell Clinic > Articles by: admin

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

By Global News Feed

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the presentation of two posters related to its clinical studies in support of biosimilarity and clinical comparability of Alvotech’s ATV04 (ustekinumab) and the reference product Stelara® at the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21 in New Orleans.

Here is the original post:
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

CancerVax Universal Cancer Vaccine Being Developed by UCLA

By Global News Feed

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells. The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.

Read this article:
CancerVax Universal Cancer Vaccine Being Developed by UCLA

Better Choice’s Halo Pet Food Brand Awarded "2022 Consumer’s Favorite Imported Cat Brand" by the China Pet Industry White Paper

By Global News Feed

After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported cat food category After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported cat food category

Read the rest here:
Better Choice’s Halo Pet Food Brand Awarded "2022 Consumer’s Favorite Imported Cat Brand" by the China Pet Industry White Paper

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

By Global News Feed

BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Read the original:
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

Celyad Oncology to announce full year 2022 financial results and host conference call

By Global News Feed

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd.

Read this article:
Celyad Oncology to announce full year 2022 financial results and host conference call

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

By Global News Feed

ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks at the 2023 HAEi Regional Conference APAC, taking place in Bangkok, Thailand, on March 17-19, 2023.

Follow this link:
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

By Global News Feed

WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA, March 17-21) new data from its INTEGUMENT-1 and INTEGUMENT-2 pivotal Phase 3 studies of roflumilast cream 0.15% in adults and children 6 years and older with mild to moderate atopic dermatitis (AD). Roflumilast cream is a once-daily, steroid-free topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor.

Visit link:
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

→←